Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced hERG Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Neomorphic IDH2R140Q mutation is commonly found in acute myeloid leukemia (AML), and inhibiting its activity has been validated as an effective treatment for AML. Herein, we report a series of highly potent and selective IDH2R140Q inhibitors. Among them, compound 36 was identified as the most promising inhibitor, with an IC50 value of 29 nM and more than 490-fold selectivity over wild-type IDH2. The compound significantly suppressed D2HG production (IC50 = 10 nM) and induced differentiation in TF-1/IDH2R140Q cells. Furthermore, it showed reasonable pharmacokinetic properties with high bioavailability (F = 90.3%) and an appropriate half-life (T1/2 = 6.4 h). In vivo, oral administration of compound 36 at a dose of 25 mg/kg effectively reduced D2HG levels in the tumor of TF-1/IDH2R140Q xenograft mouse model. Besides, compound 36 displayed little effect on the hERG current. These results suggest that compound 36 has the potential to be an efficacious treatment for AML.

[1]  Rasha Abdelhady,et al.  Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents , 2023, Journal of enzyme inhibition and medicinal chemistry.

[2]  S. Dusza,et al.  Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia. , 2022, Leukemia research.

[3]  H. Kantarjian,et al.  Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome , 2022, Blood advances.

[4]  L. Newell,et al.  Advances in acute myeloid leukemia , 2021, BMJ.

[5]  Hai Yan,et al.  The implications of IDH mutations for cancer development and therapy , 2021, Nature Reviews Clinical Oncology.

[6]  Ligong Lu,et al.  Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China , 2021, Acta pharmaceutica Sinica. B.

[7]  C. Dinardo,et al.  Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia , 2021, American journal of hematology.

[8]  F. Appelbaum,et al.  NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  S. Weiler,et al.  Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature , 2020, Journal of clinical medicine.

[10]  H. Döhner,et al.  Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. , 2020, Blood.

[11]  Robert Abel,et al.  Is structure based drug design ready for selectivity optimization? , 2020, bioRxiv.

[12]  Yisheng Lai,et al.  Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants , 2020, Comput. Biol. Chem..

[13]  Jie Yang,et al.  Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells , 2020, Cell Communication and Signaling.

[14]  Weiliang Zhu,et al.  Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free Energy Predictions. , 2019, ACS chemical neuroscience.

[15]  L. Lou,et al.  Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants , 2019, Cancer science.

[16]  Li Li,et al.  Structure-Based Drug Design Strategies and Challenges. , 2018, Current topics in medicinal chemistry.

[17]  Esther S. Kim,et al.  Enasidenib: First Global Approval , 2017, Drugs.

[18]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[19]  M. Konopleva,et al.  Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML , 2015, American journal of hematology.

[20]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[21]  M. Carroll,et al.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies , 2014, Leukemia.

[22]  Benoît Roux,et al.  Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. , 2013, Journal of the American Chemical Society.

[23]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[24]  Jing Wu,et al.  Alterations of metabolic genes and metabolites in cancer. , 2012, Seminars in cell & developmental biology.

[25]  H. Kubo,et al.  The increase in surface CXCR4 expression on lung extravascular neutrophils and its effects on neutrophils during endotoxin-induced lung injury , 2011, Cellular and Molecular Immunology.

[26]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[27]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[28]  Hai Yan,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.

[29]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[30]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[31]  T. Nomura,et al.  Human acute myeloblastic leukemia-ascites model using the human GM-CSF- and IL-3-releasing transgenic SCID mice , 1999, Annals of Hematology.

[32]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[33]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[34]  M. Sekijima,et al.  Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach. , 2018, Journal of molecular graphics & modelling.